期刊文献+

晚期上皮性卵巢癌预后的相关因素分析 被引量:1

Analysis of prognostic factors in advanced epithelial ovarian cancer
下载PDF
导出
摘要 目的探讨影响晚期卵巢癌预后的相关因素。方法对Ⅲ~Ⅳ期原发性上皮性卵巢癌患者共119例的临床病理资料进行回顾性分析,采用Kaplan-Meier法进行生存时间分析,用Cox风险比例回归模型对影响预后的因素进行多因素分析。结果91例Ⅲc期卵巢癌患者的3、5年生存率分别为55.42%和35.62%,Ⅳ期(6例)的3年生存率仅为30.14%。88例残余肿瘤直径≤2cm患者3、5年生存率分别为58.31%和38.83%,高于残余肿瘤直径>2cm者(P<0.05)。组织学分化为G2和G3者,3年(46.82%)及5年(31.53%)生存率明显低于G1者(P<0.05)。比较术前CA125<500U/ml,500~5000U/ml,以及>5000U/ml3组患者的生存情况,发现各组的远期生存率差异无统计学意义(P>0.05)。Cox风险比例回归模型进行多因素分析,发现手术病理分期[相对危险度(RR)=2.473,P=0.025],组织学分化[RR=2.316,P=0.033]及残余肿瘤的直径[RR=3.584,P=0.001]是独立预后因素。结论手术病理分期、组织学分化、残留肿瘤的直径是晚期卵巢癌独立的预后因素。 Objective To investigate the relationship between survival and the various prognostic factors in patients with advanced epithelial ovarian cancer. Methods A retrospective analysis was conducted on 119 patients with stage Ⅲ - IV ovarian cancer at our Department between January 1997 and December 2002. Outcomes of patients were studied by the method of Kaplan-Meier and compared by means of the log-rank test. Multivariate cox regression models were used to assess the correlatious between survival and the various prognostic factors. Results Ninety-one patients with stage Ⅲ c disease had 3-year o- verall survival (OS) and 5-year OS of 55.42% and 35.62% respectively, whereas the stage Ⅳ patients only had 30.14% 3- year OS. Eighty-eight patients with residual tumor size≤2cm had significantly better outcomes (58.31% in 3-year OS and 38. 83% in 5-year OS) compared with those having residual tumor size 〉 2cm ( P 〈 0.05 ). The patients with tumor grade of G2 and G3 had 46.82% of 3-year OS and 31.53% of 5-year OS respectively,which were worse than the outcomes in the patients with G1 (P 〈0.05 ). No significant difference was observed in OS in various levels of preoperative CAI25 subgroups, including CA125 〈 500U/ml,500 - 5 000U/ml and 〈 5 000U/ml, respectively ( P 〉 0.05 ). Multivariate analysis confirmed the stage ( RR =2.473,P =0.025) ,tumor grade(RR -2.316,P =0.033) ,and residual tumor size 〉2cm(RR =3. 584,P =0.001 ) as the negative independent predictors for survival. Conclusion In our study, the stage, tumor grade, and residual tumor size were independence predictors of survival for advanced ovarian cancer.
出处 《临床合理用药杂志》 2009年第16期31-33,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 上皮性卵巢癌 残余肿瘤 分化 血清CA125水平 预后 Ovarian cancer Residual tumor size Tumor grade Preoperative CA125 level Prognostic factors
  • 相关文献

参考文献3

二级参考文献34

  • 1刘继红,李孟达.卡铂腹腔化疗腹膜后淋巴结内的药物浓度[J].中华妇产科杂志,1995,30(5):273-275. 被引量:24
  • 2李孟达,黄欣.中、晚期卵巢癌综合治疗疗效及影响因素的分析[J].中华妇产科杂志,1996,31(10):621-623. 被引量:35
  • 3连利娟 林巧稚.妇科肿瘤学[M](第3版)[M].北京:人民卫生出版社,2000.586.
  • 4Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol , 1991, 9: 1138-1150.
  • 5van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol, 1989 ,7: 769-773.
  • 6Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer, 1991, 27: 1367-1372.
  • 7Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage Ⅲ epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol , 1992, 47: 159-166.
  • 8Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer, 1993, 71: 606-614.
  • 9Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer, 1993, 71: 1534-1540.
  • 10Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage Ⅲ epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 1992,47: 159-166.

共引文献35

同被引文献12

  • 1李春颖,吴鸣,原劲阳.血小板及纤维蛋白原对卵巢癌患者病情进展的影响[J].中国医学科学院学报,2009,31(1):81-83. 被引量:7
  • 2李孟达,李玉洁,黄永文,黄鹤.影响上皮性卵巢癌远期疗效的因素分析[J].癌症,2004,23(11):1306-1310. 被引量:19
  • 3Whitehouse C, Solomon E. Current status of the molecular character- izafion of the ovarian cancer antigen CA125 and implications for its use in clinical screening [ J ]. Gynecol 0ncol,2003,88 : 152 - 157.
  • 4Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cell by caspase-9-independcnt activation of caspase-3 [ J ]. Mol Cancer Ther,2005,4:217 - 224.
  • 5Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer[J]. lnt J Gynaecol Obstet,2006,95(Suppl 10) :S161 - S192.
  • 6Pierluigi BP, Angelo MN. Systematic aortic and pelvic lymphadenecto- my versus resection of bulky nodes only in optimally debulked ad- vanced ovarian cancer:a randomized clinical trial [ J ]. J Natl Cancer Inst,2005,97 (8) :560 -566.
  • 7Nuray B, Kunter Y, Mustafa B, et al. Correlation of platelet count with seeond-looklaparotomy results and disease progression in patients with advanced epithelial ovarian cancer [ J]. Obstet Gynecol, 2004, 103 (1) :82 -85.
  • 8Li A J, Madden AC, Cass I,et al. The prognostic significance of throm- bocytosis in epithelial ovarian carcinoma [ J ]. Gynecologic Oncology, 2004,92:211 - 214.
  • 9Rebecca L, Stone I, Alpa M, et al. Paraneoplastic thrombocytosis in o- varian cancer [ J ]. N Engl J Med,2012,366 ( 7 ) :610 - 618.
  • 10刘侃,陈红晓,张虹.晚期卵巢癌预后相关因素分析[J].现代妇产科进展,2010,19(12):918-921. 被引量:6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部